"Psoriasis Cream Succeeds in Early Trial" - Kristen Monaco
An investigational, topical cream that inhibits phosphodiesterase type 4 (PDE-4) was effective at clearing plaque psoriasis in a double-blind, phase IIb trial.
Meeting the trial's primary endpoint, 28% of patients treated with a 0.3% concentration of roflumilast and 23% of patients on a lower dose (0.15%) had clear or almost clear skin after 6 weeks, as compared to 8% of those given a placebo cream (P<0.001 and P=0.004 vs placebo, respectively), reported Mark Lebwohl, MD, of the Icahn School of Medicine at Mount Sinai in New York City, and colleagues.
Mount Sinai Researchers Discover That Topical Treatment Improves Chronic Plaque Psoriasis
Jul 15, 2020 View All Press Releases